Skip to main content
. 2021 May 31;13(6):e14062. doi: 10.15252/emmm.202114062

Table 9.

France.

(A) 04 – 09/12/2020
Position Location Mutation Count Incidence
241nt 5´UTR CG → TG 116/116 prevalent
noneffective
1,059nt nsp2 CC → TC 16/116 prevalent
ACC (Threonine) → ATC (Isoleucine)
2,416nt CA → TA 25/116 CN,ES,RU,US, ZA
noneffective
3,037nt nsp3 CT → TT 115/116 prevalent
noneffective
4,543nt CA → TA 15/116 DE,ES
CAC (Histidine) → TAC (Tyrosine)
5,629nt GT → TT 15/116 DE,ES
noneffective
8,371nt GG → TG 23/116 ES,RU
CAGGTA (Glutamine Valine) → CATGTA (Histidine Valine)
9,526nt nsp4 GT → TT 15/116 DE,ES
ATGTCA (Methionine Serine) → ATTTCA (Isoleucine Serine)
11,497nt nsp6 CT → TT 15/116 DE,ES
noneffective
13,993nt RNA‐dependent RNA polymerase GC → TC 15/116 DE,ES
GCT (Alanine) → TCT (Serine)
14,408nt CT → TT 114/116 prevalent
CCT (Proline) → CTT (Leucine)
15,324nt CA → TA 22/116 BR,CN,IN
noneffective
15,766nt GT → TT 15/116 DE,ES
GTG (Valine) → TTG (Leucine)
16,889nt Helicase AA → GA 15/116 DE,ES
AAA (Lysine) → AGA (Arginine)
17,019nt GT → TT 15/116 DE,ES
GAGTTT (Glutamic Acid Phenylalanine) → GATTTT
(Aspartic Acid Phenylalanine)
20,268nt endoRNAse AG → GG 13/116 ES,RU,US,
noneffective ZA
22,992nt Spike glycoprotein GC → AC 15/116 DE,US
AGC (Serine) → AAC (Asparagine)
23,403nt AT → GT 116/116 prevalent
GAT (Aspartic Acid) → GGT (Glycine)
25,563nt ORF3a protein GA → TA 57/116 prevalent
CAGAGC (Glutamine Serine) → CATAGC (Histidine Serine)
25,710nt CT → TT 16/116 DE,ES
noneffective
26,735nt Membrane glycoprotein CA → TA 15/116 DE,ES,IN,
noneffective US
26,876nt TC → CC 15/116 DE,ES
noneffective
28,833nt Nucleocapsid phosphoprotein CA → TA 12/116 ES
TCA (Serine) → TTA (Leucine)
28,851nt GT → TT 10/116 IN
AGT (Serine) → ATT (Isoleucine)
28,881nt GGG → AAC 17/116 prevalent
AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine)
28,975nt GT → CT 15/116 DE,ES,IN
ATGTCT (Methionine Serine) → ATCTCT (Isoleucine Serine)
29,399nt GC → AC 15/116 DE,ES
GCT (Alanine) → ACT (Threonine)
(B) 01/19/2020–01/20/2021
Position Location Mutation Total Count Percentage
222nt 5´UTR C → T 100 3.77
241nt C → T 2,600 98
313nt ORF1ab polyprotein → leader protein C → T 55 2.07
445nt T → C 163 6.14
1,059nt nsp2 C → T 385 14.51
2,416nt C → T 320 12.06
3,037nt nsp3 C → T 2,606 98.23
3,099nt C → T 69 2.6
4,543nt C → T 666 25.1
4,960nt G → T 69 2.6
4,965nt C → T 69 2.6
5,170nt C → T 53 2
5,629nt G → T 666 25.1
6,070nt C → T 70 2.64
6,286nt C → T 168 6.33
7,303nt C → T 70 2.64
7,564nt C → T 71 2.68
8,371nt G → T 233 8.78
9,246nt nsp4 C → T 69 2.6
9,526nt G → T 667 25.14
10,279nt 3C‐like proteinase C → T 70 2.64
10,301nt C → A 69 2.6
10,525nt C → T 70 2.64
10,582nt C → T 113 4.26
10,688nt G → T 69 2.6
11,083nt nsp6 G → T 99 3.73
11,132nt G → T 54 2.04
11,497nt C → T 666 25.1
11,851nt nsp7 G → T 96 3.62
13,993nt RNA‐dependent RNA polymerase G → T 664 25.03
14,230nt C → A 68 2.56
14,408nt C → T 2,606 98.23
15,324nt C → T 467 17.6
15,738nt C → T 63 2.37
15,766nt G → T 667 25.14
16,889nt Helicase A → G 665 25.07
17,019nt G → T 665 25.07
18,877nt 3'‐to‐5' exonuclease C → T 675 25.44
20,268nt endoRNAse A → G 111 4.18
21,255nt 2'‐O‐ribose methyltransferase G → C 167 6.29
21,800nt Spike glycoprotein G → T 72 2.71
22,227nt C → T 172 6.48
22,992nt G → A 666 25.1
23,403nt A → G 2,607 98.27
25,563nt ORF3a G → T 1,474 55.56
25,688nt C → T 56 2.11
25,710nt C → T 677 25.52
26,735nt Membrane glycoprotein C → T 670 25.25
26,801nt C → G 167 6.29
26,876nt T → C 667 25.14
27,632nt ORF7a G → T 68 2.56
27,804nt ORF7b C → T 85 3.2
28,830nt Nucleocapsid phosphoprotein C → A 85 3.2
28,833nt C → T 62 2.34
28,881nt G → A 280 10.55
28,882nt G → A 277 10.44
28,883nt G → C 276 10.4
28,932nt C → T 167 6.29
28,975nt G → C 664 25.03
29,399nt G → A 662 24.95
29,402nt G → T 73 2.75
29,645nt ORF10 G → T 169 6.37
29,779nt 3´UTR G → T 67 2.53

The general design of these Tables follows the outline described in detail in the legend to Table 5 (United States). The number of sequences investigated for SARS‐CoV‐2 mutations is detailed in Tables for individual countries.